Premiums in the Affordable Care Act (ACA) Marketplace are expected to rise by an average of 18% in 2026, the steepest jump in nearly a decade. For millions of individuals and families who depend on the Marketplace for coverage, it’s a real affordability crisis.
The Kaiser Family Foundation’s Health System Tracker highlights several forces driving this increase: medical inflation, workforce costs, hospital consolidation, and rising utilization. But one cost driver is consistently underestimated in public debates: prescription drugs.
Prescription Drugs: The Silent Premium Driver
Specialty medications, particularly GLP-1s, are having an outside influence on the drug spend curve. These therapies are clinically valuable, extremely popular with members, but their rapid adoption and price tags are pushing budgets to the limit. As costs rise, plan sponsors must adjust cost-sharing to maintain value. The result is that every Marketplace enrollee pays more, whether or not they use these more expensive therapies.
This mirrors what we’ve seen across commercial and Medicaid plans: prescription drug costs remain the fastest-growing and least-controlled category of healthcare spending. Unlike hospital or physician costs, which are somewhat constrained by market rates and reimbursement policy, drug costs can escalate unchecked when waste and inefficiencies go unaddressed.
Why Marketplace Members Feel the Pain First
ACA Marketplace members are disproportionately sensitive to cost. Because the marketplace is designed for people without employer coverage, i.e. self-employed or work for small businesses, higher premiums hit them directly, often forcing tough tradeoffs like downgrading coverage or going without insurance.
ACA plans qualify for the Premium tax credit, and the credit is tied to benchmark plans. So, when the benchmark goes up, the subsidies must also rise. That drives up federal spending and, for states administering Medicaid expansion populations, increases their share of costs under the Federal Medical Assistance Percentage (FMAP). In short, premium hikes translate into higher subsidies and mounting budget pressures for both federal and state governments.
Cutting Waste Without Cutting Care
Containing premium growth requires tackling prescription drug waste at the root. That’s where RazorMetrics makes the difference.
Our physician-directed platform:
- Identifies clinically sound alternatives—generics, biosimilars, and therapeutic equivalents.
- Supports deprescribing where medications may no longer be necessary or effective.
- Engages physicians directly within their normal workflow, preserving care quality and adherence.
- Delivers transparent, measurable savings to members and plan sponsors—without cutting benefits or restricting access.
- FMAP Advantage: As a technology platform, RazorMetrics’ costs may qualify for the Federal Medical Assistance Percentage (FMAP) — helping reduce both state and federal Medicaid spend.
By bending the drug cost curve, we help plans reduce claim spend and slow the premium spiral. That’s not theory, it’s happening today. Across employers, public plans, and Medicaid programs, RazorMetrics has delivered double-digit ROI by reducing waste while protecting member health.
Premium Hikes Aren’t Inevitable
The projected 18% ACA premium hike in 2026 is a warning signal. Without intervention, escalating drug costs will continue to erode affordability across the Marketplace and beyond. Plan sponsors need solutions that address prescription drug waste directly, not after the fact.
At RazorMetrics, we believe smarter, physician-directed interventions can contain costs while safeguarding access. For members facing higher premiums and tighter budgets, that difference is more than financial, it’s central to their healthcare.
